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ABSTRACT: The binding of interleukin-17A (IL-17A) to its receptor causes the release of chemokine which 
have an implication in the pathogenesis of gouty arthritis. Though, some synthetic drugs have been proved 
worthy as IL-17A inhibitors in the management of gout but they have been associated with a number of side 
effects. Polyphenols have been documented for numerous therapeutic applications. In spite of this, there are 
scarce data on the mechanism of action and protective potentials of polyphenolic against gouty arthritis. This 
present in silico study aimed to assess the inhibitory potentials and ADMET properties of selected 
polyphenols against IL-17A using molecular docking tools. The crystal structure of IL-17A was retrieved 
from the protein database, while the structures of polyphenolic compounds were retrieved from Pubchem. 
Drug-likeness of the polyphenols was assessed using DruLiTo. A total of 22 out of 26 polyphenols 
investigated passed the Lipinski drug likeness rule of five which were then docked with the active site of IL-
17A using docking software, and the docked complexes were analyzed using LigPlot and protein-ligand 
profiler web server. The results showed that all the investigated polyphenols have appreciable higher binding 
affinity when compared to the standard drug (allopurinol) with pelargondin and catechin having the highest 
binding affinity (-7.5 kcal/mol). Furthermore, ADMET screening were carried out on the five compounds with 
the best hits. Conclusively, this in silico study suggests that these investigated polyphenols could serve as 
better replacements for synthetic drugs such as allopurinol in the management of gouty arthritis. 
Keywords: Gouty arthritis; Inflammation; Interleukins; In silico; Phenolics; ADMET. 
1. INTRODUCTION 
Gout, a prevalent chronic arthritis with every 9.5% to 13.5% per 1,000 persons becoming affected [1, 
2]. The pathophysiology of this disease is chiefly due to the improper uric acid metabolism leading to the 
precipitation and accumulation of uric acid crystals in joints, bones, tissues, and other organs [1]. Therefore, 
gout is also called hyperuricemia [3]. Gout is more common in male compared to female base on the ratio of 
4:1. Although, the rate increases in women post-menopause [1, 4]. Furthermore, individuals with gout are at 
risk of developing chronic kidney disease, cardiovascular diseases, metabolic disorders, and psychosis [5-9]. 
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During purine metabolism, hypoxanthine and xanthine are produced, and then metabolized in the liver to uric 
acid. The reaction is catalyzed by xanthine oxidase [10]. Humans lack uricase, an enzyme that degrades uric 
acid to soluble allantoin; therefore, uric acid is not degraded leading to the accumulation of insoluble uric acid 
crystals in joints, bones, and many other organs like kidney [11-13]. According to Kostalova et al. [10], 
xanthine oxidase is a key player in the pathogenesis of gouty arthritis and its inhibition is crucial in the 
management of the pathological condition [10]. 
Cytokines of the interleukin-17 family promote the maintenance of both adaptive and innate immunity 
[14-17]. Dysregulation of their production may contribute to inflammatory and autoimmune diseases such as 
rheumatoid arthritis, psoriasis and asthma [14, 15, 17, 18]; as such, the aforementioned facts has drawn 
researchers’ attention to target them for therapeutic purposes. The roles played by interleukins in protective 
immunity could be complicated by the aggravation of autoimmune diseases such as rheumatoid arthritis, 
psoriasis, multiple sclerosis, systemic lupus erythematosus, autoimmune hepatitis and different forms of 
cancer development [19-21] as several studies have reported that serum or urinary levels of interleukin 17A 
(IL-17A) are significantly elevated in patients with these pathologies [22-27]. 
Interleukins play critical roles in the pathogenesis of gout especially IL-17A and IL-18 which are 
proinflammatory cytokines that are upregulated in the serum of gout patients [11, 22, 25]. Most notably, IL-
17A is involved in the inflammatory process during infection and in the pathogenesis of chronic inflammation 
in autoimmune diseases via mediating the recruitment of neutrophils and macrophages during inflammation 
[19, 21, 28,]. IL-17A is a significant proinflammatory cytokine produced by T-helper 17 (Th17), gamma delta 
T (γδ T) and natural killer (NK) cells [29]. Previous reports have shown that IL-17 is present at sites of 
inflammatory arthritis and its synergistic interactions amplifies the inflammation induced by other cytokines, 
including IL-1, IL-6, IL-8, and TNF-α [19, 25, 28, 30]. In addition, Zhou et al. [31] reported that excess 
chemokines are released into the blood of gouty patients when IL-17A binds to its receptor. 
Plants possess a wide variety of chemical compounds which are products of secondary metabolism and 
these phytoconstituents exhibit therapeutic properties including anti-inflammatory activity; which appear to 
have great potentials for synthesizing new drugs in the management of infectious diseases [32, 33]. 
Polyphenols, a wide family of phytochemicals with numerous biological properties, and this make them 
attract considerable attention. For instance, the immunomodulatory property polyphenols play a central role in 
the regulation of immune systems in humans [34]. Besides, the biological activities of polyphenols depend 
crucially on their chemical structures and the biotransformation undergone in the biological system [34]. 
Oliviero et al. [35] reported that polyphenols play a dual role in the management of gout arthritis viz; 
inhibition of xanthine oxidase thereby decreasing the production of uric acid and acting as an anti-
inflammatory agent via inhibition of pro-inflammatory genes involved in canonical inflammatory and 
apoptotic pathways. The inhibited pathways are NF-B signaling pathway which leads to IL-1 transcription 
and inflammasome activation which allows the release of IL-1 into the extracellular space [35]. 
Allopurinol is a drug used for long-term management of hyperuricemia. Mechanistically, allopurinol 
competitively inhibits xanthine oxidase, an enzyme responsible for uric acid production [36]. Though, 
synthetic drugs such as allopurinol are effective in the management of gouty arthritis which may be due to 
their ability to target and inhibit IL-17A, however, they are usually accompanied with several complications 
such as gastrointestinal distress, hypersensitivity reactions, skin rash, elevated blood glucose and pressure, 
diarrhea, and vomiting in patients [1, 37-39]. Therefore, it is pertinent to identify plant-based compounds with 
IL-17A inhibitory potential in silico. Hence, this present in silico study aimed to assess the inhibitory 
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potentials of selected polyphenols against IL-17A using molecular docking tools and screening the best hit 
compounds for their ADMET properties in silico. 
2. MATERIALS AND METHODS 
2.1. Macromolecule’s structure retrieval and Prediction of active site 
The structure of IL-17A (PDB ID: 4HR9) was retrieved from Protein Data Bank (PDB). Because                 
IL-17A is a homodimer (chain A and B) protein, we only used chain A for our docking studies. The other 
chain and water molecules were removed using software tool Chimera©, version 1.13., 
(http://www.cgl.ucsf.edu/chimera), the proteins were prepared for docking by removing the co-crystallized 
ligand and additional water molecules to make it as a nascent receptor [40]. The binding pocket of the 
receptor was predicted via DogSite platform of protein-plus webserver (http://proteinsplus.zbh.uni-
hamburg.de) base on the drugability of pockets identified [41]. The amino acid residues in the predicted 
pocket was further compared with those identified through extensive literature mining. 
2.2. Ligands’ structures retrieval and preparations 
Twenty-six phenolic compounds vis; apigenin, caffeic acid, catechins, chlorogenic acid, p-coumaric 
acid, curcumin, cyanidin, ellagic acid, epicatechin, ferulic acid, gallic acid, genistein, glycitein, hesperetin, 
isoquercitrin, kaempferol, luteolin, malvidin, naringenin, pelargondin, pyrocatechol, pyrogallol, quercitrin, 
quercetin, resorcinol and rutin were selected for the ligand protein docking study. The docking study was 
performed against a standard drug (allopurinol). The molecular structures of the ligand (polyphenols) as well 
as that of the standard drug were retrieved from Pubchem database. The structures were retrieved in SDF 
format and were converted to mole files using MarvinSketch© (ver. 15.11.30). The molecules were then 
minimized using the Merck molecular force field (MMFF94) algorithm in Avogadro (ver. 1.10). 
2.3. Drug likeliness screening 
The selected molecules were screened for drug likeliness as described by Lipinski et al. [42]. The 
molecules were analyzed using DruLiTo software to calculate their logP, molecular weight, hydrogen bond 
donors and acceptors values. The lipinski’s rule of five was applied to screen for the probable molecules [43]. 
2.4. Molecular docking 
Auto Dock Vina [44] was utilized for the molecular docking analysis of the selected ligands with the 
protein target. The protein data bank, partial charge, and atom type (PDBQT) file of the protein was generated 
through this software (using the previously created PDB file as input). The specific target site of the protein 
was set -with the help of grid box. The X, Y, and Z dimensions were set to 38.39 × 25.00 × 32.25, the X, Y 
and Z centers were adjusted based on the active site reviewed from literatures of the protein target [1, 14, 25]. 
Once the molecular dockings were completed and 10 configurations for each protein-ligand complex were 
generated for all the compounds using the software, text files of scoring results were also generated for the 
purpose of manual comparative analysis. For each of the compounds, the docking runs were done ten (10) 
times consecutively with the number of modes set to 10 in order to enhance the accuracy and reliability of the 
outputs. The protein-ligand complexes were prepared with the aid of PyMOL© Molecular Graphics (version 
1.3, 2010, Shrodinger LLC), as well as the 2D molecular interactions were visualized using BIOVIA 
Discovery Studio 2016 [45].  
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2.5. ADMET properties prediction of the best hit compounds 
ADMET (Adsorption, Distribution, Metabolism, Excretion and Toxicity) is key to analyze the 
pharmacodynamics and pharmacokinetics of the compounds having best docking hits as they could be used as 
a drug. A two-step prediction was deployed to screen them for i) the aqueous solubility, druglikeness and 
medicinal chemistry filters with the aid of SWISSADME servers [46]; and ii) their ADMET properties with 
the aid of ADMETSar and SWISSADME servers [46-48]. 
3. RESULTS AND DISCUSSION 
Over the years, plants are confirmed to have medicinal properties that were used in the management of 
many pathological conditions [49-54]. Though, traditional therapy has been overshadowed by modern 
medicine to manage human health. But, the past few decades have witnessed an increase in the application of 
phytomedicines for orthodox therapy [55]. Interleukin 17A have been implicated in the pathogenesis of gout 
arthritis [11, 22, 25] and available synthetic drugs are accompanied with a number of side effects alongside 
their therapeutic efficacies [1, 39]. Hence, in this present in silico study, we used molecular docking technique 
to investigate the ability of some polyphenolic compounds to inhibit the action of IL-17A. 
Twenty-six (26) phenolic compounds and a reference drug (allopurinol) were selected and assessed for 
their inhibitory potentials against IL-17A. The structure of these compounds (ligands) was obtained from 
pubchem. For in silico analysis of phenolic compounds, the drug potential of all the ligands was accessed 
using the Lipinski’s rule of five via the DruLiTo© software. Lipinski rule of five is a rule to evaluate drug 
likeness and to determine if a chemical compound possesses a certain pharmacological or biological activity 
to make it an orally active drug in humans [42, 43]. The compound that exceeds molecular weight (Mw) > 500 
Da, calculated log P > 5, hydrogen-bond donors > 5 and hydrogen-bond acceptors >10 is unlikely to be 
further pursued as a potential drug, because it would likely lack properties essential for absorption, 
distribution, metabolism and excretion [42, 43, 56, 57]. The data we obtained from the drug likeliness 
screening revealed that 22 out of the 26 screened compounds passed the Lipinski’s rule of five. Non-violation 
of drug likeliness rule by the 22 compounds indicates that these compounds will likely possess good 
absorption, molecular flexibility, oral bioavailability and ability to reach their target site of action when 
ingested [42, 43, 56, 57]. The four compounds that we eliminated from further docking analysis for violating 
at least one of the rules are chlorogenic acid, isoquercitrin, quercitrin and rutin (Table 1). 
The 3D structure of IL-17A (4hr9) was retrieved from Protein Database (Fig. 1) with resolution of 
2.48Å. IL-17A consist of 155 amino acid sequences; a disulfide-linked, homodimeric (chain A and B) secreted 
glycoprotein with a molecular mass of 35kDa [14, 21, 58]. The amino acid residues in the active site of IL-
17A after extensive literature search are; Tyr43, Tyr44, Trp51, Leu53, Tyr62, Pro63, Val65, Ile66, Trp67, 
Ala69, Ile92, Gln94, Glu95, Ile96, Leu97, Val98, Leu99, Leu112, Lys114, Val117, Ser118, Val119, Glu120 
and Cys121 [1, 14, 25]. A novelty was included in this study even though we were able to get the amino acid 
residues from literatures, DogSite platform from the protein-plus web server (http://proteinsplus.zbh.uni-
hamburg.de) was deployed to predict the druggable pocket of the target receptor, IL-17A. according to [41], 
the pocket with the highest drug score is likely to be the binding site of a given receptor. As results of these, 
the predicted druggable pocket consist of the following amino acid residues; Pro19, Arg20, Thr21, Val22, 
Met23, Val24, Asn25, Leu26, Leu99, Glu102, Asn108, Ser109, Phe110, Arg111 and Leu112.  
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Table 1. Lipinski properties of selected polyphenols analyzed using DruLiTo© software tool. 

















1.  Allopurinol 135401907 136.04 -0.443 2 5 0 
2.  Apigenin 5280443 270.05 1.138 3 5 0 
3.  Caffeic acid 689043 180.04 0.888 3 4 0 
4.  Catechin 73160 290.08 0.852 5 6 0 
5.  Chlorogenic acid 1794427 354.1 -0.7 6 9 1 
6.  p-Coumaric acid 1549106 164.05 0.751 2 3 0 
7.  Curcumin 9695161 368.13 1.945 2 6 0 
8.  Cyanidin 128861 287.06 1.967 5 5 0 
9.  Ellagic acid 5281855 302.01 1.366 4 8 0 
10.  Epicatechin 72276 290.08 0.852 5 6 0 
11.  Ferulic acid 445858 194.06 0.78 2 4 0 
12.  Gallic acid 370 170.02 0.964 4 5 0 
13.  Genistein 5280961 270.05 1.043 3 5 0 
14.  Glycitein 5317750 284.07 1.364 2 5 0 
15.  Hesperetin 72281 302.08 1.03 3 6 0 
16.  Isoquercitrin 5280804 464.1 0.099 8 12 2 
17.  Kaempferol 5280863 286.05 1.486 4 6 0 
18.  Luteolin 5280445 286.05 1.486 4 6 0 
19.  Malvidin 159287 331.08 2.099 4 6 0 
20.  Naringenin 932 272.07 0.79 3 5 0 
21.  Pelargondin 440832 271.06 1.619 4 4 0 
22.  Pyrocatechol 289 110.04 1.083 2 2 0 
23.  Pyrogallol 1057 126.03 1.431 3 3 0 
24.  Quercitrin 5280459 448.1 0.802 7 11 2 
25.  Quecertin 5280343 302.04 1.834 5 7 0 
26.  Resorcinol 5054 110.04 0.654 2 2 0 
27.  Rutin 5280805 610.15 -0.735 10 16 3 
 
 
Figure 1. Three dimensional and homodimeric structure of interleukin-17A. Chain A in blue and chain B in red. 
 
Autodock Vina in Python Prescription 0.8 suite, PyMOL, and Discovery studio 2016 were used to 
determine the binding energies, binding poses, and best orientation of ligands with targets as shown in Table 2 
and Fig. 2. Results from this research study indicated that the binding affinity between the ligands and IL-17A 
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were stabilized by non-covalent bonds such as hydrogen bonds, hydrophobic bonds and pie-type interactions. 
One of the long-standing intentions of structural biologists is to broadly define the specific roles of hydrogen 
bonds in protein structures and functions [59]. The effect of hydrogen bonding in stabilizing the molecular 
interaction between the ligands and the protein cannot be ignored because of its critical roles in enzyme 
catalysis, protein-substrate and protein-inhibitor complexes, as well as structural stability of various biological 
molecules [60]. In addition, the capacity to possess a positive charge at the physiological pH despite being in 
covalent bond within molecules is a unique feature possessed by it [60]. Similarly, hydrophobic interactions 
are considered to be indispensable in many systems such as micelles, vesicles, colloids, membranes and 
transport; self-organization, polymer interactions, protein folding and ligand binding, nucleic acids, drug 
action, and water-mediated organic reaction. Indeed, hydrophobic interaction is one of the most reverent 
intermolecular forces [59]. Recently, researchers have reported that the binding affinity of ligands to a target 
protein is directly proportional with the hydrophobic interactions between the ligands and the hydrophobic 
amino acid residues found in the target’s binding site [60, 61]. This could have actually accounted for the 
appreciable binding affinity of 19 out of the 22 compounds docked against IL-17A studied in this work as 
compared to allopurinol (Fig. 2).  
 
 
Figure 2. Molecular docking of Allopurinol with IL-17A. a) 3D binding pose of allopurinol after docking experiment  
with IL-17A generated using PyMOL. Allopurinol binds to a different site on IL-17A. b) 2D interaction prepared using 
Discovery Studio. 
 
The results of this study revealed that interaction between allopurinol and the selected polyphenols 
with the amino acid residues within the active site of IL-17A (Fig. 2-3). In other words, all investigated 
compounds fit into the active cavity of IL-17A, an achievement that might likely prevent IL-17A to bind with 
its receptor, consequently preventing the release of chemokines. Allopurinol, one the most commonly used 
xanthine oxidase inhibitor, reduces oxidative stress in the vasculature, improves endothelial function in a 
variety of cardiovascular disease states, and reduces expression of proinflammatory molecules such as soluble 
intercellular adhesion molecule-1 (ICAM-1) in vitro [62]. The findings from this present in silico study 
showed that when compared with the selected polyphenols, allopurinol had the highest (least effective) 
binding energy of -4.8 kcal/mol when docked with IL-17A which resulted in the formation of hydrogen bond 
with Tyr44, Asp45 and Trp51; hydrophobic interaction with Ser47, Pro50, Trp51, Leu53 and Arg72 and an 
BE= -4.8 kcal/mol 
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additional interaction with Trp51 via π-stacking (Fig. 2 and Table 2). Both catechin and pelargondin had the 
lowest (most effective) binding energy of -7.5 kcal/mol (Table 2). Catechin formed hydrogen bond with 
Asn108 and Phe110; also, established hydrophobic interaction with Val24, Leu26, Leu99, Phe110, Arg111 and 
Leu112 while pelargondin established hydrophobic interaction with Arg20, Thr21, Val22, Leu26, Leu99, 
Ser109, Phe110 and Arg111 when docked against IL-17A; it aromatic rings interacted with Val22, Val24 and 
Leu112 through pie bond formation. Pelargondin formed no hydrogen bond but majorly hydrophobic and pie-
bonds with Arg20, Thr21, Met23, Leu26, Leu99, Asn108 and Leu112; and Val22, Val24 and Phe110 
respectively. The interactions exhibited by these polyphenols agree with previous findings that these amino 
acid residues are involved in their contact with IL-17A receptor [14, 21]. From our findings, 19 polyphenols 
exhibited better interactions with amino acid residues in the active site of IL-17A than allopurinol which 
might be responsible for their better binding affinities.  
 























Ser47, Pro50, Trp51, 
Leu53 and Arg72 
Trp51 
Apigenin -7.0 1 Arg20 2.86 
Arg20, Val24, Leu26, 
Leu99, Asn108, Phe110 
and Leu112 
- 





Val24, Leu26, Leu99, 
Phe110, Arg111 and 
Leu112 
- 





Arg20, Thr21, Val22, 
Leu26, Leu99, Ser109, 
Phe110 and Arg111 
Val22, Val24 
and Leu112 
Curcumin -6.7 1 Leu112 3.26 
Val22, Met23, Val24, 
Leu26, Leu99, Phe110 
and Arg111 
- 





Tyr43, Tyr44, Asp45 
and Trp51 
- 





Val22, Val24, Leu99, 
Arg111 and Leu112 
- 






Val22, Met23, Val24, 












Tyr44 and Leu53 Tyr44 







Val24, Leu99 and 
Asn108 
Phe110 





Tyr44, Ser47, Thr48, 
Trp51, Ile92, Gly120 
and Cys121 
Tyr44 





Tyr44, Ser47, Thr48, 
Trp51, Ile92, Gly120, 
Cys121 and Thr122 
Tyr44 





Tyr44, Ser47, Ser49, 
Trp51, Ile92,Val119, 
Gly120, Cys121 and 
Thr122 
Tyr44 





Arg20, Thr21, Met23, 
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Luteolin -6.9 1 Leu112 3.92 
Val22, Val24, Leu26, 
Leu99, Phe110, Arg111 
and Leu112 
- 





Tyr43, Tyr44, Asp45, 
Trp51, Leu53, Trp67and 
Val119 
Tyr44 
Naringenin -7.1 - - - 
Val22, Val24, Leu26, 










Val22, Met23, Leu99, 
Phe110 and Leu112 
- 
Pelargondin -7.5 - - - 
Arg20, Thr21, Met23, 




Pyrocatechol -4.1 1 Phe110 3.15 
Val24, Leu99, Asn108 
and Ser109 
Phe110 














Arg20, Thr21, Met23, 











Tyr43, Tyr44 and Asp45 Tyr44 
 
 
Figure 3. Molecular docking of five hit compounds with IL-17A. a) 3D binding pose catechin (white), epicatechin 
(orange), kaempferol (blue), pelargondin (red) and quercetin (yellow) bind to the same site on IL-17A. 2D interactions              
of b) catechin, c) epicatechin, d) kaempferol, e) pelargondin and f) quercetin with the amino acid residues of IL-17A. 
 
Polyphenols belongs to the class of naturally occurring compounds that are mostly found in vegetables, 
fruits, beverages, and cereals [34]. More than 500 unique polyphenols are collectively called phytochemicals. 
It has been documented that regular consumption of polyphenol-rich diets is beneficial for the brain and 
cardiovascular system, as well as the immune system [34]. Owing to their extensive pharmacological and 
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bioactive properties, polyphenols are widely studied and demonstrated their usefulness in the prevention and 
treatment of disease [63]. The anti-inflammatory and immunomodulatory activity of polyphenols have 
attracted huge attention for years [35]. It is shown that continuous and long-lasting inflammation can be the 
major cause of cardiovascular diseases, cancer, neurodegenerative diseases, diabetes type II, arthritis, and 
obesity [64]. In this regard, the anti-inflammatory characteristic of polyphenols is contributed to their 
antioxidant activity, such as ROS scavenging in addition to their ability to alter the expression of several pro-
inflammatory genes like nitric oxide synthases, cyclooxygenase, multiple cytokines, and lipoxygenases [34, 
35, 63, 64]. Conversely, polyphenols modulate the immune system through the modification in cytokines 
production, immune cell populations, and pro-inflammatory gene expression [34]. According to Fan et al. 
[65], catechin exhibit anti-inflammatory properties via the regulation of NF-kB, MAPKs and Nrf2 pathways. 
Pelargondin has been reported to be the main anthocyanin in fruits and vegetables that is responsible for the 
anti-inflammatory effect, antioxidant and antidiabetic potentials in vivo [63, 64, 66]. According to Li et al. 
[67], quercetin, found in fruits, vegetables, leaves and grains; is known for anti-inflammatory potentials, mast 
cell stabilizing and gastro-intestinal cytoprotective activity. Epicatechin, an isomer of catechin, was reported 
to inhibit TNF-α, IL-6, PGE2 and Nitric oxide by Wang and Cao [68]. Kaempferol is majorly from 
Zingiberaceae kaempferia which its numerous beneficial functions had been reported as cardiovascular, 
antioxidant, antidiabetic, anti-inflammatory, hepatoprotective and neuroprotctive effects [69]. Naringenin is 
mainly found in citrus fruits such as lemon, orange, tangerine and grapefruit, it inhibits inflammation stimuli 
in several models of inflammatory pain [70, 71]. Apigenin is present principally as glycosylated in significant 
amount in onions, oranges, chamomile, thyme, tea, beer, and wine [72]. According to Fidelis et al. [73], a 
huge number of reports in the literature have confirmed the antioxidant properties of apigenin. In addition, 
anti-hyperglycemic [74], anti-inflammatory [75], and anti-apoptotic effects (in myocardial ischemia) [76] 
have been reported. Numerous pharmacological activities, including antioxidant and antimicrobial properties, 
have been attributed to curcumin [77]. Hesperetin is mainly found in citrus fruits; an aglycone of hesperidin, 
possesses a well-documented antioxidant efficacy as reported to have prevented inflammation and apoptosis 
as evidenced by its ability to lowering the levels of proinflammatory cytokines and caspase-3 activity in 
diabetic rats [78, 79]. The high binding affinities observed among the selected polyphenols in this in silico 
study might be a major contributor to their extensive bioactive and pharmacological properties. 
After the in silico molecular docking analysis, 17 compounds with binding energies below -6.0 
Kcal/mol to the least (Table 2) were chosen and their aqueous solubility, druglikeness filters and medicinal 
chemistry predicted through SwissAdme server (Table 3). All the compounds are soluble in water as predicted 
which are in an agreement with their predicted lipophilicity (Table 1). The druglikeness filters predicted 
herein are lipinski’s, Ghose’s, Veber’s, Egan’s and Muegge’s. 12 compounds show no violations to these 
filters. The bioavailability scores range were good except for chlorogenic acid. 6 compounds were predicted 
to have one problematic fragment (in these case catechol A) under PAINS (for pan assay interference 
compounds, that is frequent hitters or promiscuous compounds) [46]. 15 compounds show leadlikeness 
ability. Finally, the ease to modify these compounds fall between 1.76 and 4.16. 
Furthermore, 5 hit compounds (Table 2) namely; catechin, epicatechin, kaempferol, pelargondin and 
quercetin with allopurinol, were screened for their ADMET properties using ADMETSar and SwissAdme 
servers [46-48]. Table 4 show the classes and properties predicted for these compounds. Allopurinol was 
predicted to permeant the blood-brain barrier, quercetin had a low human oral availability and it might serve 
as substrate to p-glycoprotein (also pelargondin).  
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score PAINS Leadlikeness 
Synthetic 
accessibility 














Yes Yes Yes Yes Yes 0.55 0 Yes 2.96 
























































Yes Yes Yes Yes Yes 0.55 0 Yes 2.95 
Hesperetin Soluble Yes Yes Yes Yes Yes 0.55 0 Yes 3.22 








Malvidin Soluble Yes Yes Yes Yes Yes 0.55 0 Yes 3.33 
Naringenin Soluble Yes Yes Yes Yes Yes 0.55 0 Yes 3.01 
Pelargondin Soluble Yes Yes Yes Yes Yes 0.55 0 Yes 3.04 




PAINS = pan assay interference compounds; MW = Molecular weight; MR = Molar refractivity; TPSA = topological surface area; WlogP = lipophilicity; H-don = Hydrogen bond donors; #atoms = No of atoms. 
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Table 4. ADMET properties of some selected drugs approved globally for the management of Covid-19 patients. 




Yes No No No No No 
Caco-2 
permeability 
No No No No No No 
Gastrointestinal 
Absorption 
High High High High High High 
Human Oral 
Availability 
Moderate Moderate Moderate Moderate Moderate Low 
Pgp-inhibitor No No No No No No 
Pgp-substrate No No Yes No Yes Yes 

















Mitochondria Mitochondria Mitochondria Mitochondria Nucleus Mitochondria 
Metabolism CYP450 1A2 
inhibition 
No No No Yes Yes Yes 
CYP450 3A4 
inhibition 
No No No Yes No Yes 
CYP450 3A4 
substrate 
No No No Yes No No 
CYP450 2C9 
inhibition 
No No No Yes Yes No 
CYP450 2C9 
substrate 
No No No No No No 
CYP450 2C19 
inhibition 
No No No Yes Yes No 
CYP450 2D6 
inhibition 
No No No No Yes Yes 
CYP450 2D6 
substrate 
No Yes Yes No No No 
CYP inhibitory 
promiscuity 
Low Low Low High High High 
UGT  
catalyzed 
No Yes Yes Yes Yes Yes 
Excretion Skin 
permeation 
-7.61 cm/s -7.82 cm/s -7.82 cm/s -6.70 cm/s -7.15 cm/s -7.05 cm/s 
Toxicity Acute Oral 
Toxicity 
Class iii Class iv Class iv Class ii Class ii Class ii 
hERG  
Inhibitor 
No No No No No No 
Human 
Hepatotoxicity 
Yes No No Yes Yes No 
Ames 
Mutagenicity 
Yes Yes Yes Yes No No 
Carcinogens No No No No No No 
 
All the compounds were predicted to be localized in the mitochondria except pelargondin (nucleus). 
Allopurinol show low plasma protein binding while the remaining compounds show otherwise. The poor 
binding of a compound to the plasma protein alters its efficacy to travel through plasma membrane. The 
prediction of their metabolism indicates that 3 compounds might inhibit CYP450 1A2 and 3A4 except 
pelargondin (with CYP450 3A4). Also, kaempferol and pelargondin were predicted to be inhibitors of CYP 
2C9 and 2C19. Pelargondin and quercetin were predicted to inhibit CYP 2D6; while catechin and its isomer, 
epicatechin might be metabolized by CYP 2D6. The toxicity profile indicates that none of these compounds 
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were potential carcinogens, and no ability to inhibit hERG. Although, 3 of the compounds were predicted to 
be hepatotoxic while 4 compounds show AMES mutagenicity. 
4. CONCLUSION 
In conclusion, the phenolic compounds displayed promising association to the binding site of IL-17A 
in silico and displayed some level of safety through the ADMET screening than allopurinol. Hence, this study 
proposes that these polyphenols could serve as better replacements for synthetic drugs such as allopurinol in 
the management of gouty arthritis. Prominently, the outcome from this study suggests a need to develop drugs 
for the management of gouty arthritis from plant-derived compounds. However, this in silico study is just a 
means of predicting the activity of the bioactive compounds presents in plants; so, we strongly recommend 
further studies to validate the efficacy of these phenolic compounds in the management of gouty arthritis. 
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